Development of a novel flow cytometry multiplex immunoassay for the diagnosis of celiac disease simultaneously with autoimmune diabetes

The FloCMIA multiplex immunoassay was successfully developed as a flow cytometry-based platform for the simultaneous and discriminative screening of CD and DM1 autoantibodies. This method offers a practical, accessible, and high-throughput solution, significantly reducing costs (up to tenfold) and operational time compared to traditional assays. By utilizing a commonly available flow cytometer, detecting all immunoglobulin isotypes, and eliminating radioactive materials, FloCMIA provides a safer, more inclusive, and sensitive tool, enabling earlier therapeutic intervention and improving large-scale population screening.